Four senior FDA leaders forged close ties with Biogen well ahead of Aduhelm's approval. Now they've left FDA
Two years after the FDA’s controversial approval of Biogen’s Alzheimer’s drug Aduhelm, four of the top agency officials who came under scrutiny for their …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
